We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

41 hedge funds and large institutions have $573M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more funds holding in top 10

Funds holding in top 10: 1 → 7 (+6)

227% more capital invested

Capital invested by funds: $175M → $573M (+$397M)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

33% less funds holding

Funds holding: 61 → 41 (-20)

53% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 36

Holders
41
Holders Change
-20
Holders Change %
-32.79%
% of All Funds
0.63%
Holding in Top 10
7
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+600%
% of All Funds
0.11%
New
17
Increased
9
Reduced
10
Closed
36
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCMV
Foresite Capital Management V
California
+$102M
2
FM
Frazier Management
Washington
+$28.6M
3
RCM
RA Capital Management
Massachusetts
+$24.7M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$18M
5
EC
EcoR1 Capital
California
+$14.3M

Top Sellers

Rank Fund Capital Flow
1
ACA
Arena Capital Advisors
California
-$9.98M
2
FCM
Farallon Capital Management
California
-$9.95M
3
PHS
PFM Health Sciences
California
-$7.43M
4
SRCM
Sage Rock Capital Management
New York
-$6.62M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$2.25M +$1.6M +137,234 New
ACM
27
Altai Capital Management
California
$1.64M – – –
TD Asset Management
28
TD Asset Management
Ontario, Canada
$1.35M +$443K +38,100 +86%
HF
29
HRT Financial
New York
$1.15M -$6.46K -555 -0.8%
GTC
30
Ghost Tree Capital
New York
$819K +$582K +50,000 New
BFM
31
Boothbay Fund Management
New York
$724K +$340K +29,197 +195%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$623K -$107K -9,161 -19%
HM
33
Harvest Management
New York
$327K +$116K +10,000 +100%
Wells Fargo
34
Wells Fargo
California
$315K +$224K +19,267 New
PCM
35
Penserra Capital Management
California
$54K +$38.6K +3,317 New
CSS
36
Cubist Systematic Strategies
Connecticut
$36K +$25.7K +2,206 New
APA
37
American Portfolios Advisors
New York
$16.4K +$11.6K +1,000 New
National Bank of Canada
38
National Bank of Canada
Quebec, Canada
$16K +$11.6K +1,000 New
TRCT
39
Tower Research Capital (TRC)
New York
$5K +$3.27K +281 New
UBS Group
40
UBS Group
Switzerland
$2K -$407 -35 -19%
PHK
41
Point72 Hong Kong
Hong Kong
$1K +$396 +34 New
FCM
42
Farallon Capital Management
California
– -$9.95M -1,000,000 Closed
SRCM
43
Sage Rock Capital Management
New York
– -$6.62M -665,100 Closed
SCM
44
Suvretta Capital Management
New York
– -$3.98M -400,000 Closed
GCL
45
Glazer Capital LLC
New York
– -$2.64M -265,631 Closed
SC
46
Sculptor Capital
New York
– -$2.41M -242,000 Closed
WP
47
Woodline Partners
California
– -$2.38M -238,804 Closed
RSCM
48
Rock Springs Capital Management
Maryland
– -$2.08M -209,332 Closed
6CM
49
683 Capital Management
New York
– -$1.99M -200,288 Closed
BCM
50
BlueCrest Capital Management
Jersey
– -$1.49M -150,000 Closed
1
2
3 4

PRDS Hedge Fund Activity: Q4 2021 in Review

41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q4 2021, worth a combined $573M — up 227% from $175M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of PRDS and 17 opened new positions — a net loss of 19 holders — while 10 trimmed existing stakes and 9 added.

The largest buyer was Foresite Capital Management V, adding an estimated $102M. The largest seller was Arena Capital Advisors, cutting an estimated $9.98M.

  • 41 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q4 2021, down from 61 in Q3 2021.
  • Funds reported $573M of Pardes Biosciences, Inc. Common Stock stock for Q4 2021, up 227% quarter-over-quarter.
  • 17 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q4 2021 and 36 closed out, a net change of -19 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q4 2021 was Foresite Capital Management V, an estimated $102M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q4 2021 was Arena Capital Advisors, an estimated $9.98M sold.

Based on aggregated 13F filings for Q4 2021.